Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Francisco Navarro-Blasco
Safety and Effectiveness of Adalimumab in Patients With Rheumatoid Arthritis Over 5 Years of Therapy in a Phase 3b and Subsequent Postmarketing Observational Study
Arthritis Research and Therapy
Rheumatology
Allergy
Immunology
Related publications
Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients With Rheumatoid Arthritis in Japan
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Effectiveness, Safety, and Methotrexate Dose-Tapering Pattern Over Two Years of Treatment With Adalimumab and ≥12 Mg/Week Methotrexate for Early Rheumatoid Arthritis: Results of the HAWK Postmarketing Surveillance Study in Japan
Modern Rheumatology
Medicine
Rheumatology
Long-Term Safety and Effectiveness of Adalimumab for the Treatment of Japanese Patients With Rheumatoid Arthritis: 3-Year Results From a Postmarketing Surveillance of 552 Patients
Modern Rheumatology
Medicine
Rheumatology
OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis
Progression of Subclinical Atherosclerosis Over 5 Years in Patients With Early Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Effectiveness and Safety of Adalimumab in Patients With Ankylosing Spondylitis or Psoriatic Arthritis and History of Anti-Tumor Necrosis Factor Therapy
Arthritis Research and Therapy
Rheumatology
Allergy
Immunology
Safety Profile of Baricitinib in Patients With Active Rheumatoid Arthritis With Over 2 Years Median Time in Treatment
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Safety of Adalimumab Biosimilar MSB11022 (Acetate-Buffered Formulation) in Patients With Moderately-To-Severely Active Rheumatoid Arthritis
Clinical Rheumatology
Medicine
Rheumatology
